🧬 Aging Wiki

glycolic-acid

Properties1
aliaseshydroxyacetic acid, HOCH2COOH, 2-hydroxyacetic acid, glycollate

13 min read

Glycolic Acid

The smallest alpha-hydroxy acid (AHA; 2-carbon backbone). Used as an OTC cosmetic exfoliant at 5–15% concentrations and as a medical-grade chemical-peeling agent at 20–70% concentrations. Acts via pH-dependent dissolution of corneodesmosomal adhesion between stratum corneum corneocytes. At peel-grade concentrations, elicits a controlled wounding response that stimulates dermal collagen neosynthesis. Decades of dermatology RCTs establish efficacy for photoaging, melasma, and mild acne. A 2025 network meta-analysis of 23 RCTs placed glycolic acid as most effective among topical agents for skin surface roughness reduction 1. FDA-cleared/approved in multiple medical-device and OTC cosmetic formulations.

Identity

FieldValue
PubChem CID757
InChIKeyAEMRFAOFKBGASW-UHFFFAOYSA-N
CAS (primary)79-14-1
ChEMBLCHEMBL252557
DrugBankDB03085
HMDBHMDB0000115
Molecular formulaC2H4O3
Molecular weight76.05 Da
Classalpha-hydroxy acid (AHA); smallest member of the class
pKa~3.83 (aqueous)
Solubilityfreely water-soluble; miscible with ethanol
Canonical SMILESC(C(=O)O)O

Glycolic acid is the 2-carbon alpha-hydroxy acid (glycolate when ionized). Its small size confers deeper epidermal penetration compared to larger AHAs (lactic acid 3-carbon, mandelic acid 9-carbon) at equivalent concentrations and pH — making it both the most potent and most irritating AHA for topical use. dose-response-unclear (optimal concentration × pH × contact-time titration for each indication remains empirically defined without a unified pharmacokinetic model).

Mechanism of action

pH-dependent corneodesmosmal dissolution (cosmetic-grade)

Efficacy is governed by free-acid concentration, not total acid concentration. The undissociated form (RCOOH) is the skin-penetrant species. At pH 3.5–5.0, a proportion of glycolic acid molecules remain uncharged; these partition into the intercorneocyte lipid lamellae of the stratum corneum. Once inside, the acid dissociates, locally reducing pH. The calcium-dependent serine proteases kallikrein-5 (KLK5) and kallikrein-7 (KLK7), which process desmoglein-1 and corneodesmosin to enable natural shedding, are inhibited at physiological pH (~5.5) but their activity is restored or enhanced at lower pH — the net result is accelerated corneodesmosmal dissolution and increased desquamation. unsourced (KLK5/KLK7 regulation by AHA-induced pH lowering — this mechanism is described in the desquamation biology literature (Egelrud, Rawlings) but is not stated in Almeman 2024; needs primary citation to KLK5/KLK7 desquamation studies)

The key regulatory implication: a product containing 10% glycolic acid at pH 7.0 contains essentially zero undissociated acid (Henderson-Hasselbalch: at pH 7, with pKa 3.83, >99.9% is carboxylate anion). This product is inert as an exfoliant. At pH 3.5, ~17% is in free-acid form (~1.7% effective concentration from a 10% formulation). pH is the primary determinant of efficacy — not the labeled percentage. Almeman 2024 affirms that concentration and pH are both critical for therapeutic efficacy and that optimal concentrations for minimizing adverse effects remain under investigation 2.

Deeper epidermal action (medium-concentration peels, 20–35%)

At concentrations above ~20% applied at pH < 3.5 for 2–5 minutes, glycolic acid penetrates through the stratum granulosum into the stratum spinosum, causing controlled keratinocyte cytotoxicity. This triggers epidermal regeneration from the basal layer and initiates a mild wounding response with keratinocyte growth factor (KGF) and IL-1α secretion, stimulating keratinocyte proliferation and normalizing differentiation 2. The consequence is replacement of a photo-damaged, irregularly differentiated epidermis with a more uniformly organized one.

Papillary dermis wounding and collagen neosynthesis (peel-grade, 35–70%)

At 35–70% concentrations, penetration reaches the papillary dermis. Controlled wounding of the dermis triggers the wound-healing cascade: (1) transient inflammation with cytokine release (IL-1, TNF-α, TGF-β1); (2) fibroblast activation; (3) type I collagen synthesis and organized deposition. Histologically, treated skin shows a thickened epidermis, compact stratum corneum, and new papillary dermal collagen 3 4. This mechanism is functionally similar to dermatologic-resurfacing (laser, dermabrasion) but achieves shallower depth with less downtime. See chemical-peels (class MOC) for comparison across peel depth/modality.

Note on mechanism vs. “acid” labeling: Early dermatology literature attributed glycolic acid’s efficacy to “acid reduction of skin pH” or “ionic calcium chelation.” The corneodesmosome-dissolution model (via free-acid partitioning and KLK regulation) supersedes those framings but the mechanistic picture is still not fully resolved at the molecular level. no-mechanism for the precise molecular target of KLK modulation by glycolic acid.

Concentration Ă— depth table

ConcentrationpH rangePenetration depthPrimary effectSetting
5–10% (leave-on)3.5–5.0Stratum corneum surfaceCorneocyte desquamation; surface textureOTC cosmetic
10–20% (leave-on/peel)3.0–4.0Stratum corneum → granulosumAccelerated epidermal turnover; mild brighteningOTC/professional
20–35% (superficial peel)2.5–3.5Stratum spinosumKeratinocyte regeneration; photoaging correctionIn-office, supervised
35–50% (medium-superficial peel)2.0–3.0Stratum basale → superficial papillary dermisWounding response; collagen stimulationMedical office
50–70% (medium-depth peel)1.5–2.5Papillary dermisNeocollagenesis; substantial resurfacing; 3–7 day recoveryDermatologist setting

Higher concentrations + lower pH → deeper penetration. Neutralization terminates the reaction; practitioners apply glycolic acid and neutralize with bicarbonate solution at the desired endpoint (erythema grade, frosting pattern).

Clinical indications and efficacy

Photoaging (fine wrinkles, pigmentation, texture)

Multiple RCTs demonstrate improvement in photoaging composite scores, fine lines, surface roughness, mottled pigmentation, and skin tone with repeated glycolic acid peel series (typically 4–6 peels at 2–4 week intervals) 3 4 5. A 2025 network meta-analysis of 23 RCTs (n=3905 participants) examining topical agents for facial photoaging ranked glycolic acid as most effective for surface roughness reduction among the tested agents (OR 120.00 vs placebo), with isotretinoin ranking highest for fine wrinkle improvement, tazarotene most effective for coarse wrinkles, and tretinoin having the most favorable safety profile 1. Tazarotene had the worst safety profile of all agents tested (significantly higher adverse events vs placebo). This represents the highest-level summary evidence to date.

The 2025 NMA also found that glycolic acid and tretinoin occupied different parts of the photoaging composite — glycolic acid excels at surface-texture normalization (stratum corneum-level) while retinoids show superior recovery of dermal collagen architecture (RAR-mediated transcriptional neocollagenesis over months-to-years of continuous use). The two mechanisms are complementary, which underpins their frequent clinical co-deployment 1.

Discordance note vs training-era citations: Older single-center RCTs frequently showed glycolic acid “equivalent to retinoids” on photoaging global assessments 6. The 2025 NMA does not replicate this equivalence for fine-wrinkle improvement specifically — glycolic acid failed to reach statistical significance for fine wrinkles (OR 2.36, 95% CI [0.56, 10.06], p=0.2413) while isotretinoin, retinol, and tretinoin all showed significant effects. For fine wrinkles, glycolic acid and tazarotene demonstrated lower cumulative probabilities than the retinoid class. The NMA is the higher-level evidence; earlier equivalence findings likely reflect the global-assessment outcome conflating surface roughness (where glycolic excels) with fine-wrinkle depth (where retinoids are superior). contradictory-evidence between older single-center equivalence claims and the 2025 NMA’s differential ranking by outcome dimension.

Melasma

Glycolic acid 70% peel series is as effective as tretinoin 1% peel series for melasma based on a double-blind bilateral RCT (n=63 females) 6, with tretinoin causing significantly less discomfort. Glycolic acid in combination with hydroquinone + tretinoin (Kligman-type regimen) is a standard-of-care approach for refractory melasma; glycolic acid’s role is to increase penetration of the depigmenting agents by removing the corneal barrier. Combination with ascorbic-acid and/or niacinamide is common.

Acne (mild-moderate)

Glycolic acid accelerates comedone resolution by normalizing follicular desquamation (complementary to salicylic-acid, which is lipid-soluble and penetrates the sebaceous follicle directly). Clinical use at 20–35% peels every 2–4 weeks reduces inflammatory and non-inflammatory acne counts. Evidence is moderate-quality (small RCTs with variable endpoints) 2.

Seborrheic keratoses; early actinic keratoses

Glycolic acid 35–70% peels soften and partially ablate seborrheic keratoses; combined with curettage or cryotherapy. For actinic keratoses, peel series reduce AK counts in clinical studies, though cryotherapy and topical fluorouracil remain first-line for individual lesions.

Tolerability and safety

Cosmetic-grade (5–15%): Transient stinging on application (resolves in seconds), occasional mild erythema. Well-tolerated in Fitzpatrick I–III. Requires sunscreen use (increased UVB photosensitivity for ~1 week after leave-on use at pH < 3.5) 2.

Medical-grade peels (20–70%): Immediate erythema, stinging (mild to intense), erythematous desquamation 2–5 days post-peel (at ≥35%). Recovery 3–7 days for medium-depth peels. Downtime is the primary tolerability barrier for the 50–70% range. Post-inflammatory hyperpigmentation (PIH) risk is substantially higher in Fitzpatrick IV–VI skin types — lower starting concentration, shorter contact time, and test-patch protocols are mandatory. Never use > 30% glycolic acid without appropriate supervision in darker skin phototypes.

Systemic absorption: Topical glycolic acid at cosmetic concentrations does not produce measurable systemic exposure in normal use — the compound is metabolized via the glyoxylate pathway to CO2/H2O if systemically absorbed. Not a systemic safety concern at OTC use levels.

Comparison to other AHAs and peeling agents

CompoundCarbon chainpKaWater solubilityPenetration depth at given concHumectancyNotes
Glycolic acid2C3.83Freely miscibleDeepest of AHAsLowSmallest = deepest penetration
lactic-acid3C3.86Freely miscibleIntermediateHigh (intrinsic humectant)Better tolerated; natural skin component
Mandelic acid9C3.41LimitedShallowest of AHAsLowUsed in sensitive skin; antimicrobial
salicylic-acidBHA2.97LipophilicFollicular (sebaceous)NoneComplements glycolic for acne; distinct mechanism

Among AHAs, glycolic acid’s 2-carbon backbone confers the smallest molecular size and deepest penetration at equivalent pH/concentration. This translates to both higher efficacy and higher irritation potential compared to larger AHAs. lactic-acid (3-carbon; similar pKa) offers comparable exfoliation with additional humectant benefit and is preferred for dry or sensitive skin types. salicylic-acid is a beta-hydroxy acid (BHA) with lipid solubility enabling follicular penetration — distinct from AHAs and complementary for acne/oily skin indications.

Combination and sequencing

With retinoids (tretinoin, retinol, retinaldehyde): Glycolic acid (cosmetic-grade, OTC) + retinoid: alternate application (e.g., glycolic in morning, retinoid at night) to manage irritation stack. The mechanisms are mechanistically orthogonal and clinically additive — glycolic accelerates surface cell turnover and smooths texture; retinoids drive dermal collagen transcription and normalize differentiation over longer timeframes. Do not apply simultaneously to avoid cumulative irritation.

With niacinamide: Compatible and complementary — glycolic provides exfoliation; niacinamide supports barrier ceramide synthesis (counteracting glycolic’s mild barrier disruption) and inhibits melanin transfer (synergy for hyperpigmentation). Can be applied in the same routine; if irritation occurs, separate by time-of-day.

With ascorbic-acid: Complementary — ascorbic acid is a cofactor for collagen prolyl hydroxylase and inhibits melanin precursor (dopaquinone) re-oxidation. Stable ascorbic acid formulations work best at low pH (~3.0–3.5) — which is in the same pH range as glycolic acid formulations; combination serums exist. At overlapping pH, glycolic may slightly extend ascorbic acid stability.

With uv-protection (sunscreen): Mandatory. Any AHA use increases UV photosensitivity for approximately 7 days (more pronounced with leave-on products at therapeutic pH). Sunscreen SPF 30+ is the standard co-prescriptive recommendation.

With other peeling agents (TCA, Jessner’s solution): Glycolic + TCA combination peels achieve medium-depth resurfacing (papillary dermis) with lower glycolic concentration than glycolic alone. The Yenny 2024 split-hand study found glycolic 20% + TCA 15% combination superior to glycolic 20% alone for hand photoaging pigmentation and aging scores (n=69) 7.

Aging-hallmark context

The primary aging relevance of glycolic acid is topical photoaging reversal:

  • loss-of-proteostasis (via collagen neosynthesis at peel-grade concentrations): photoaged dermis has fragmented type I collagen and elevated MMPs; peel-grade glycolic acid elicits a wound-healing response that deposits new collagen. Histologically confirmed at 50% concentration, double-blind vehicle-controlled 3.
  • skin-aging (canonical phenotype): glycolic acid directly targets the canonical manifestations of photoaging (fine wrinkles, surface roughness, mottled pigmentation, seborrheic keratosis development).

Glycolic acid does not directly target systemic hallmarks of aging (senescence, mTOR, mitochondria). Its aging relevance is entirely in the topical-dermatological domain. This places it in the same category as tretinoin, niacinamide, ascorbic-acid, and uv-protection — a skin-aging intervention without systemic geroprotective evidence.

Extrapolation context

DimensionStatus
Pathway conserved in humans?yes (corneodesmosome biology is human-specific data)
Phenotype conserved in humans?yes (all RCT data is directly in human skin)
Replicated in humans?yes — multiple decades of RCTs; 2025 NMA of 23 RCTs

This compound’s evidence base is almost entirely human — unlike most compounds in this wiki which are predominantly rodent-based. The translation gap is not rodent-to-human extrapolation but rather concentration-specificity: OTC cosmetic-grade data (10–15%) does not extrapolate directly to medical-grade peel data (35–70%), which should not be performed without clinical supervision.

Limitations and gaps

  • Mechanism incompletely resolved: The KLK5/KLK7 corneodesmosome-dissolution model is plausible and consistent with clinical observations but the precise molecular interaction of glycolic acid with these enzymes has not been fully characterized in controlled in vitro assays. no-mechanism (KLK5/KLK7 regulation by glycolic acid)
  • Concentration Ă— pH optimization: Clinical peel protocols are empirically derived; no pharmacokinetic model has been validated for predicting effective tissue-level pH at a given product concentration, pH, and contact time. dose-response-unclear
  • Head-to-head RCT vs retinoids for collagen endpoints: The 2025 NMA 1 provides the best indirect comparison but no direct RCT has compared peel-grade glycolic acid to continuous tretinoin using dermis-depth collagen quantification as primary endpoint. The discordance between texture-improvement (favors glycolic) and fine-wrinkle improvement (favors tretinoin) endpoints requires resolution in a single well-powered head-to-head study. needs-replication
  • Long-term data at high concentrations: Most RCTs have < 3-month follow-up. Whether 35–70% peel-driven collagen deposition is maintained, or whether repeated peeling over years leads to dermal atrophy or other complications, is not well documented. long-term-unknown
  • PIH in Fitzpatrick IV–VI: Substantial risk; well-recognized but not systematically quantified across all AHA product classes at various concentrations. Most RCT populations are Fitzpatrick I–III. needs-human-replication for skin-of-color populations
  • No aging indication–specific RCT: All glycolic acid clinical evidence is in dermatological conditions (photoaging, melasma, acne) — no RCT has enrolled an aging-defined primary endpoint (e.g., biological skin age by VISIA or biophysical skin-age composite). This is a conceptual gap rather than an evidence weakness.

Footnotes

Footnotes

  1. doi:10.1038/s41598-025-12597-0 · Lin L, Chen X, Liu C et al. (co-first: Lin L, Chen X; corresponding: Xu Z) · Scientific Reports 2025 · network meta-analysis · 23 RCTs, n=3905 participants · glycolic acid ranked most effective for surface roughness reduction (OR 120.00, 95% CI [7.54, 1908.99], p=0.0007); isotretinoin ranked highest for fine wrinkle improvement (OR 116.23); tazarotene most effective for coarse wrinkles; tretinoin had the most favorable safety profile; tazarotene had the worst safety profile (significantly higher adverse events vs placebo) · locally downloaded PDF available at DOI lookup ↩ ↩2 ↩3 ↩4

  2. doi:10.2147/CCID.S453243 · Almeman AA · Clinical, Cosmetic and Investigational Dermatology 2024 · comprehensive narrative review of AHA efficacy, safety, regulatory landscape, and market analysis in dermatological practice; covers glycolic + lactic + mandelic + malic + citric + tartaric acids; summarizes RCT evidence for photoaging, acne, melasma, hyperpigmentation; mechanism framed as corneocyte-cohesion disruption + apoptosis induction (caspase pathways) + collagen/elastin synthesis stimulation; affirms that concentration and pH are critical for therapeutic efficacy and that optimal concentrations remain under investigation; does NOT discuss KLK5/KLK7 serine-protease mechanism or Henderson-Hasselbalch free-acid calculation explicitly · locally downloaded PDF available at DOI lookup ↩ ↩2 ↩3 ↩4

  3. doi:10.1111/j.1524-4725.1996.tb00347.x · Newman N, Newman A, Moy LS, Babapour R, Harris AG, Moy RL · Dermatologic Surgery 1996 · n=~20 · double-blind vehicle-controlled · 50% glycolic acid peel × 4 weekly sessions → stratum corneum thinning, increased epidermal thickness, new papillary dermal collagen on histology; texture and wrinkling improvement on clinical grading · citation percentile 98% (FWCI 6.19) · not OA; archive status: not_oa ↩ ↩2 ↩3

  4. doi:10.1111/j.1346-8138.2006.00003.x · Yamamoto Y, Uede K, Yonei N, Kishioka A, Ohtani T, Furukawa F · Journal of Dermatology 2006 · controlled histological study · 6-week daily application of glycolic, lactic, citric, acetic acids in Japanese subjects; glycolic + lactic produced greatest reductions in epidermal melanin and increases in dermal collagen density vs other AHAs tested · citation percentile 99% (FWCI 5.18) · not OA; archive status: not_oa ↩ ↩2

  5. doi:10.1097/01.prs.0000156142.12128.81 · Rubino C, Farace F, Dessy LA, Sanna A, Mazzarello V · Plastic and Reconstructive Surgery 2005 · n=NR · randomized double-blind · 12-week topical glycolic acid vs multivitamin vs placebo; silicone replica analysis; glycolic acid significantly reduced microsulcus parameters (crow’s feet); vitamin treatments ns · citation percentile 96% · not OA; archive status: not_oa ↩

  6. PMID 22134569 · Faghihi G, Siadat AH et al. · Journal of Drugs in Dermatology 2011 · n=63 female melasma patients · double-blind bilateral RCT · tretinoin 1% peel vs glycolic acid 70% peel; equivalent efficacy; tretinoin significantly less patient discomfort · DOI not available in PubMed ArticleIdList; cite by PMID only ↩ ↩2

  7. doi:10.1111/jocd.16456 · Yenny SW, Ilmiawati C · Journal of Cosmetic Dermatology 2024 · n=69 · split-hand controlled study · glycolic acid 20% alone vs glycolic 20% + TCA 15% combination for hand photoaging; combination significantly superior for pigmentation + dermoscopic aging markers · citation percentile 100% (FWCI 2.37) · hybrid OA; archive pending ↩

Graph View

Backlinks